SCHEMBL4250780

SCHEMBL4250780

O=C(Nc1ccc(-c2nnc(S(=O)(=O)Cc3ccccc3)o2)c(Cl)c1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 1/20 0.47
NPC1 O15118 4/20 0.47
SENP1 Q9P0U3 1/20 0.45
GRM4 Q14833 1/20 0.44
ACE2 Q9BYF1 1/20 0.43
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
AGPAT2 O15120 1/20 0.42
KMT2A Q03164 3/20 0.41
KCNK3 O14649 2/20 0.41
KCNK9 Q9NPC2 2/20 0.41
CNR1 P21554 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4246981 0.88 CHRNA7 (0.51) RAB9AKDM4EALDH1A1MAPTPOLB
SCHEMBL4247033 0.88 CHRNA7 (0.54) RAB9AKDM4EALDH1A1MAPTNPC1
SCHEMBL4247364 0.85 MAPT (0.47) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL4238834 0.83 HPGD (0.49) ALDH1A1MAPTPOLBGRM4KCNK3
SCHEMBL4242232 0.83 ALDH1A1 (0.52) RAB9AKDM4EALDH1A1MAPTPOLB
SCHEMBL4247100 0.79 ALDH1A1 (0.67) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL13878316 0.79 RAB9A (0.56) RAB9AKDM4EALDH1A1MAPTPOLB
SCHEMBL4036871 0.78 CHRNA7 (0.52) RAB9AKDM4EMAPTNPC1KMT2A
SCHEMBL4242077 0.76 CHRNA7 (0.56) RAB9AKDM4EALDH1A1MAPTNPC1
SCHEMBL4243114 0.76 CHRNA7 (0.55) RAB9AKDM4EALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
WO-2007138033-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA2 RAB9A 2045/4885KDM4E 3074/4885ALDH1A1 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.